/
Respiratory
COPD
21
Pipeline Programs↗
81
Active Trials↗
43
Companies Involved↗
COPD is an emerging landscape with 21 programs across 43 companies. The most active players are Pfizer, Areteia Therapeutics. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 13
Phase 24
Phase 34
Approved
No programs
Analysis
Trial Status
232
clinical trials
Completed127 · 55%
Recruiting35 · 15%
Not yet recruiting31 · 13%
Active, not recruiting13 · 6%
Unknown status12 · 5%
Terminated6 · 3%
Other8 · 3%
Clinical Trials
Trial Activity
232 trials
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Recruiting·—·Phase 2·NCT07037836·10 enrolled
Cognitive Load-Induced Inhaler Errors in COPD: Linking Dual-Task Mobility to Treatment Self-Management
Recruiting·Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie Dr. Victor Babeș Timișoara·Preclinical·NCT07786220·100 enrolled
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)